Reengineering the tumor microenvironment to alleviate hypoxia and overcome cancer heterogeneity

Cold Spring Harbor Perspectives in Medicine

Volumn 6, Issue 12, 2016, Pages

  Martin, John D ^a,b   Fukumura, Dai ^a   Duda, Dan G ^a   Boucher, Yves ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; ANGIOGENESIS INHIBITOR; CYTOTOXIN; VASCULOTROPIN A;

ACIDOSIS; ARTICLE; CANCER CELL; CELL COMPONENT; DECOMPRESSION; EXTRACELLULAR MATRIX; GENETIC ENGINEERING; GENETIC HETEROGENEITY; HUMAN; HYPOXIA; INTRATUMORAL PRESSURE; MALIGNANT NEOPLASM; METABOLISM; NONHUMAN; ONCOLOGICAL PARAMETERS; OXYGENATION; PRESSURE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY;

ANGIOGENESIS INHIBITORS; CYTOTOXINS; HUMANS; HYPOXIA; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85005975967     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a027094     Document Type: Article

References (245)

1. Adam MF, Gabalski EC, Bloch DA, Oehlert JW, Brown JM, Elsaid AA, Pinto HA, Terris DJ. 1999. Tissue oxygen distribution in head and neck cancer patients. HeadNeck 21: 146–153.
2. Albrengues J, Bourget I, Pons C, Butet V, Hofman P, Tartare- Deckert S, Feral CC, Meneguzzi G, Gaggioli C. 2014. LIF mediates proinvasive activation of stromal fibroblasts in cancer. Cell Rep 7: 1664–1678.
3. Albrengues J, Bertero T, Grasset E, Bonan S, Maiel M, Bourget I, Philippe C, Herraiz Serrano C, Benamar S, Croce O, et al. 2015. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat Commun 6: 10204.
4. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen- Dale AL. 2013. Signatures of mutational processes in human cancer. Nature 500: 415–421.
5. Alitalo K. 2011. The lymphatic vasculature in disease. Nat Med 17: 1371–1380.
6. Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Munoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, et al. 2013. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer 109: 926–933.
7. Apte MV, Park S, Phillips PA, Santucci N, Goldstein D, Kumar RK, Ramm GA, Buchler M, Friess H, McCarroll JA, et al. 2004. Desmoplastic reaction in pancreatic cancer: Role of pancreatic stellate cells. Pancreas 29: 179–187.
8. Arjaans M, OudeMunnink TH, Oosting SF, Terwisscha van Scheltinga AG, Gietema JA, Garbacik ET, Timmer-Bosscha H, Lub-de Hooge MN, Schroder CP, de Vries EG. 2013. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res 73: 3347–3355.
9. Auvinen P, Tammi R, Kosma VM, Sironen R, Soini Y, Mannermaa A, Tumelius R, Uljas E, Tammi M. 2013. Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. Int J Cancer 132: 531–539.
10. Bailey JM, Swanson BJ, Hamada T, Eggers JP, Singh PK, Caffery T, Ouellette MM, Hollingsworth MA. 2008. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res 14: 5995–6004.
11. Baish JW, Netti PA, Jain RK. 1997. Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. Microvasc Res 53: 128–141.
12. Baish JW, Stylianopoulos T, Lanning RM, Kamoun WS, Fukumura D, Munn LL, Jain RK. 2011. Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc Natl Acad Sci 108: 1799–1803.
13. Bar EE. 2011. Glioblastoma, cancer stem cells and hypoxia. Brain Pathol 21: 119–129.
14. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, et al. 2013. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci 110: 19059–19064.
15. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL. 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331: 1612–1616.
16. Bedard PL, Hansen AR, Ratain MJ, Siu LL. 2013. Tumour heterogeneity in the clinic. Nature 501: 355–364.
17. Bindra RS, Crosby ME, Glazer PM. 2007. Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev 26: 249–260.
18. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E. 2003. Levels of hypoxia-inducible factor-1a independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97: 1573–1581.
19. Boucher Y, Jain RK. 1992. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: Implications for vascular collapse. Cancer Res 52: 5110–5114.
20. Boucher Y, Baxter LT, Jain RK. 1990. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: Implications for therapy. Cancer Res 50: 4478–4484.
21. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S. 2007. Mammographic density and the risk and detection of breast cancer. N Engl J Med 356: 227–236.
22. Bredfeldt JS, Liu Y, Conklin MW, Keely PJ, Mackie TR, Eliceiri KW. 2014. Automated quantification of aligned collagen for human breast carcinoma prognosis. J Pathol Inform 5: 28.
23. Bristow RG, Hill RP. 2008. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8: 180–192.
24. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW. 1996. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56: 941–943.
25. Brown JM. 1979. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 52: 650–656.
26. Buffa FM, Harris AL, West CM, Miller CJ. 2010. Large metaanalysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 102: 428–435.
27. Burrell RA, McGranahan N, Bartek J, Swanton C. 2013. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501: 338–345.
28. Butcher DT, Alliston T, Weaver VM. 2009. A tense situation: Forcing tumour progression.Nat Rev Cancer 9: 108–122.
29. Butler JM, Kobayashi H, Rafii S. 2010. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors.Nat Rev Cancer 10: 138–146.
30. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, et al. 2007. A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69–82.
31. Carmeliet P, Jain RK. 2011a. Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298–307.
32. Carmeliet P, Jain RK. 2011b. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10: 417–427.
33. Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, et al. 2015. Randomized phase Ib/II study of gemcitabine plus placebo or Vismodegib, a Hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J Clin Oncol 33: 4284–4292.
34. Chanmee T, Ontong P, Mochizuki N, Kongtawelert P, Konno K, Itano N. 2014. Excessive hyaluronan production promotes acquisition of cancer stem cell signatures through the coordinated regulation of twist and the transforming growth factor b (TGF-b)-snail signaling axis. J Biol Chem 289: 26038–26056.
35. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. 2011. Delivery of molecular and nanoscale medicine to tumors: Transport barriers and strategies. Annu Rev Chem Biomol Eng 2: 281–298.
36. Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, Bawendi MG, Fukumura D, Jain RK. 2012. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 7: 383–388.
37. Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, Stylianopoulos T, Mousa AS, Han X, Adstamongkonkul P, et al. 2013. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun 4: 2516.
38. Chauhan VP, Boucher Y, Ferrone CR, Roberge S, Martin JD, Stylianopoulos T, Bardeesy N, DePinho RA, Padera TP, Munn LL. 2014. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure. Cancer Cell 26: 14–15.
39. Chen WJ, Ho CC, Chang YL, Chen HY, Lin CA, Ling TY, Yu SL, Yuan SS, Chen YJ, Lin CY, et al. 2014a. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat Commun 5: 3472.
40. Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, et al. 2014b. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1a/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 59: 1435–1447.
41. Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, et al. 2015. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology 61: 1591–1602.
42. Cheng G, Tse J, Jain RK, Munn LL. 2009. Micro-environmental mechanical stress controls tumor spheroid size and morphology by suppressing proliferation and inducing apoptosis in cancer cells. PLoS ONE 4: e4632.
43. Chiche J, Brahimi-Horn MC, Pouyssegur J. 2010. Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer. J Cell Mol Med 14: 771–794.
44. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC, Phillips GM, et al. 2014. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513: 559–563.
45. Conklin MW, Eickhoff JC, Riching KM, Pehlke CA, Eliceiri KW, Provenzano PP, Friedl A, Keely PJ. 2011. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol 178: 1221–1232.
46. Cooke VG, Le Bleu VS, Keskin D, Khan Z, O’Connell JT, Teng Y, Duncan MB, Xie L, Maeda G, Vong S, et al. 2012. Pericyte depletion results in hypoxia-associated epithelial- to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21: 66–81.
47. Coussens LM, Zitvogel L, Palucka AK. 2013. Neutralizing tumor-promoting chronic inflammation: A magic bullet? Science 339: 286–291.
48. Croix BS, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B. 2000. Genes expressed in human tumor endothelium. Science 289: 1197–1202.
49. Delarue M, Montel F, Vignjevic D, Prost J, Joanny JF, Cappello G. 2014. Compressive stress inhibits proliferation in tumor spheroids through a volume limitation. Biophys J 107: 1821–1828.
50. + T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16: 91–102.
51. DeNardo DG, Andreu P, Coussens LM. 2010. Interactions between lymphocytes and myeloid cells regulate proversus anti-tumor immunity. Cancer Metastasis Rev 29: 309–316.
52. De Nardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al. 2011. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1: 54–67.
53. Desmaison A, Frongia C, Grenier K, Ducommun B, Lobjois V. 2013.Mechanical stress impairs mitosis progression in multi-cellular tumor spheroids. PLoS ONE 8: e80447.
54. Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, Leblanc M, Coulter S, He M, Scott C, et al. 2013. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 153: 601–613.
55. Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG, Coussens LM, Karin M, Goldrath AW, Johnson RS. 2010. Macrophage expression of hypoxiainducible factor-1a suppresses T-cell function and promotes tumor progression. Cancer Res 70: 7465–7475.
56. Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, Jain RK. 2010. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci 107: 21677–21682.
57. DuFort CC, Paszek MJ, Weaver VM. 2011. Balancing forces: Architectural control of mechanotransduction. Nat Rev Mol Cell Biol 12: 308–319.
58. El-Kenawi AE, Ibrahim-Hashim AA, Luddy KA, Pilon-Thomas SA, Gatenby RA, Gillies RJ. 2015. Extracellular acidosis alters polarization of macrophages. Cancer Res 75: 3213–3213.
59. Elsharkawy AM, Mann DA. 2007. Nuclear factor-kB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46: 590–597.
60. Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJ, Wen PY, Ivy P, Batchelor TT, Rosen BR, et al. 2013. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med 19: 1178–1183.
61. Emblem KE, Gerstner ER, Sorensen AG, Wen PY, Batchelor TT, Jain RK. 2016. Matrix-depleting anti-hypertensives decompress tumor blood vessels and improve perfusion in patients with glioblastomas receiving anti-angiogenic therapy. AACR Annual Meeting 2016, Abstract 3975. New Orleans, LA, April 16–20.
62. Engin K, Leeper DB, Cater JR, Thistlethwaite AJ, Tupchong L, McFarlane JD. 1995. Extracellular pH distribution in human tumours. Int J Hyperthermia 11: 211–216.
63. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. 2010. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kB-dependent manner. Cancer Cell 17: 135–147.
64. Erler JT, Giaccia AJ. 2006. Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res 66: 10238–10241.
65. Erler JT, Bennewith KL, Nicolau M, Dornhöfer N, Kong C, Le QT, Chi JTA, Jeffrey SS, Giaccia AJ. 2006. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440: 1222–1226.
66. Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell HH, Ibrahim-Hashim A, Bailey K, Balagurunathan Y, Rothberg JM, Sloane BF, et al. 2013. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res 73: 1524–1535.
67. Evans SM, Du KL, Chalian AA, Mick R, Zhang PJ, Hahn SM, Quon H, Lustig R, Weinstein GS, Koch CJ. 2007. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome. Int J Radiat Oncol Biol Phys 69: 1024–1031.
68. Evans A, Armstrong S, Whelehan P, Thomson K, Rauchhaus P, Purdie C, Jordan L, Jones L, Thompson A, Vinnicombe S. 2013. Can shear-wave elastography predict response to neoadjuvant chemotherapy in women with invasive breast cancer? Br J Cancer 109: 2798–2802.
69. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L. 2011. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature 475: 226–230.
70. Fernández-Sánchez ME, Barbier S, Whitehead J, Béalle G, Michel A, Latorre-Ossa H, Rey C, Fouassier L, Claperon A, Brullé L. 2015. Mechanical induction of the tumorigenic b-catenin pathway by tumour growth pressure. Nature 523: 92–95.
71. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, et al. 2007. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109: 3812–3819.
72. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J. 2015. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527: 472–476.
73. Foernzler D, Delmar P, Kockx M, Cassidy J, Saltz L, Scherer S. 2010. Tumor tissue based biomarker analysis in NO16966: A randomized phase III study of first-line bevacizumab in combinationwith oxaliplatin-based chemotherapy in patients with mCRC. 2010 GastroIntestinal Cancers Symposium, Abstract 374. Orlando, FL, January 22–24.
74. Franzini A, Baty F, Macovei II, Durr O, Droege C, Betticher D, Grigoriu BD, Klingbiel D, Zappa F, Brutsche M. 2015. Gene expression signatures predictive of bevacizumab/ erlotinib therapeutic benefit in advanced non-squamous non-small cell lung cancer patients (SAKK 19/05 trial). Clin Cancer Res 21: 5253–5263.
75. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, et al. 1998. Tumor induction of VEGF promoter activity in stromal cells. Cell 94: 715–725.
76. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill R. 2002. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 20: 680–687.
77. Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington K, Sahai E. 2007. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 9: 1392–1400.
78. Garcia-Foncillas J, Martinez P, Lahuerta A, Cussac AL, Gonzalez MG, Sanchez Gomez RM, Alvarez I, Anton A, Illarramendi JJ, De Juan A, et al. 2012. Dynamic contrast- enhanced MRI versus 18F-misonidazol-PET/CT to predict pathologic response in bevacizumab-based neoadjuvant therapy in breast cancer. J Clin Oncol 30 (suppl; abstr 10512).
79. Gasparini G, Torino F, Ueno T, Cascinu S, Troiani T, Ballestrero A, Berardi R, Shishido J, Yoshizawa A, Mori Y, et al. 2012. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis 15: 141–150.
80. Gatenby RA, Gillies RJ. 2004. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891–899.
81. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, et al. 2003. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161: 1163–1177.
82. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, Harris AL. 2001. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61: 7992–7998.
83. Giussani M, Merlino G, Cappelletti V, Tagliabue E, Daidone MG. 2015. Tumor-extracellular matrix interactions: Identification of tools associated with breast cancer progression. Semin Cancer Biol 35: 3–10.
84. Glunde K, Guggino SE, Solaiyappan M, Pathak AP, Ichikawa Y, Bhujwalla ZM. 2003. Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia 5: 533–545.
85. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. 2011.Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91: 1071–1121.
86. Goel S, Gupta N, Walcott BP, Snuderl M, Kesler CT, Kirkpatrick ND, Heishi T, Huang Y, Martin JD, Ager E, et al. 2013. Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J Natl Cancer Inst 105: 1188–1201.
87. Goetz JG, Minguet S, Navarro-Lerida I, Lazcano JJ, Samaniego R, Calvo E, Tello M, Osteso-Ibanez T, Pellinen T, Echarri A, et al. 2011. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 146: 148–163.
88. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. 1999. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: Clinical implications. Cancer Res 59: 3776–3782.
89. Hagendoorn J, Tong R, Fukumura D, Lin Q, Lobo J, Padera TP, Xu L, Kucherlapati R, Jain RK. 2006. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res 66: 3360–3364.
90. Hah N, Sherman MH, Yu RT, Downes M, Evans RM. 2015. Targeting transcriptional and epigenetic reprogramming in stromal cells in fibrosis and cancer. Cold Spring Harb Symp Quant Biol 80: 249–255.
91. Hanley CJ, Noble F, Ward M, Bullock M, Drifka C, Mellone M, Manousopoulou A, Johnston HE, Hayden A, Thirdborough S, et al. 2016. A subset of myofibroblastic cancer- associated fibroblasts regulate collagen fiber elongation, which is prognostic in multiple cancers. Oncotarget 7: 6159–6174.
92. Haqq J, Howells LM, Garcea G, Metcalfe MS, Steward WP, Dennison AR. 2014. Pancreatic stellate cells and pancreas cancer: Current perspectives and future strategies. Eur J Cancer 50: 2570–2582.
93. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM. 2000. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156: 1363–1380.
94. Hayashi M, Yamamoto Y, Ibusuki M, Fujiwara S, Yamamoto S, Tomita S, Nakano M, Murakami K, Iyama K, Iwase H. 2012. Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer. Ann Surg Oncol 19: 3042–3049.
95. Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, Temel JS, Shaw AT, Pennell NA, Neal JW, et al. 2015. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl Acad Sci 112: 1547–1552.
96. 2 gradients in solid tumors in vivo: Highresolution measurements reveal a lack of correlation. Nat Med 3: 177–182.
97. Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK. 2002. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 8: 1284–1291.
98. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, Klagsbrun M. 2004. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 64: 8249–8255.
99. Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin SA, Gladkov OA, Holcombe RF, Korn R, et al. 2016. Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patientswith advanced pancreatic cancer. Clin Cancer Res 22: 2848–2854.
100. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. 1998.Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci 95: 4607–4612.
101. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, et al. 2012. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci 109: 17561–17566.
102. Hutchison GJ, Valentine HR, Loncaster JA, Davidson SE, Hunter RD, Roberts SA, Harris AL, Stratford IJ, Price PM, West CM. 2004. Hypoxia-inducible factor 1a expression as an intrinsic marker of hypoxia correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res 10: 8405–8412.
103. Hynes RO. 2009. The extracellular matrix: Not just pretty fibrils. Science 326: 1216–1219.
104. Incio J, Suboj P, Chin SM, Vardam-Kaur T, Liu H, Hato T, Babykutty S, Chen I, Deshpande V, Jain RK, et al. 2015. Metformin reduces desmoplasia in pancreatic cancer by reprogramming stellate cells and tumor-associated macrophages. PLoS ONE 10: e0141392.
105. Incio J, Tam J, Rahbari NN, Suboj P, McManus DT, Chin SM, Vardam T, Batista A, Babykutty S, Jung K, et al. 2016a. PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity. Clin Cancer Res 22: 2993–3004.
106. Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, Ng MR, Nia HT, Grahovac J, Kao S, et al. 2016b. Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. Cancer Discov doi: 10.1158/2159-8290.
107. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis D, Agnantis N, Pavlidis N. 2002. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IVand laminin in breast cancer: Their prognostic value and role in tumour invasion and progression. Eur J Cancer 38: 2362–2370.
108. Ishii G, Ochiai A, Neri S. 2015. Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv Drug Deliv Rev 99: 186–196.
109. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, et al. 2013. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62: 112–120.
110. Jain RK. 1988. Determinants of tumor blood flow: A review. Cancer Res 48: 2641–2658.
111. Jain RK. 2001. Normalizing tumor vasculature with antiangiogenic therapy: A new paradigm for combination therapy. Nat Med 7: 987–989.
112. Jain RK. 2003. Molecular regulation of vessel maturation. Nat Med 9: 685–693.
113. Jain RK. 2005. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307: 58–62.
114. Jain RK. 2014. Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell 26: 605–622.
115. Jain RK, Tong RT, Munn LL. 2007. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: Insights from a mathematical model. Cancer Res 67: 2729–2735.
116. Jain RK, Martin JD, Stylianopoulos T. 2014. The role of mechanical forces in tumor growth and therapy. Annu Rev Biomed Eng 16: 321–346.
117. Jayson GC, Kerbel R, Ellis LM, Harris AL. 2016. Antiangiogenic therapy in oncology: Current status and future directions. Lancet 388: 518–529.
118. Jeong HS, Jones D, Liao S, Wattson DA, Cui CH, Duda DG, Willett CG, Jain RK, Padera TP. 2015. Investigation of the lack of angiogenesis in the formation of lymph node metastases. J Natl Cancer Inst 107: djv155.
119. Joyce JA, Pollard JW. 2009. Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239–252.
120. Junttila MR, de Sauvage FJ. 2013. Influence of tumour micro- environment heterogeneity on therapeutic response. Nature 501: 346–354.
121. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, deWilde PC, Bussink J, Raleigh JA, van der Kogel AJ. 2002. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62: 7066–7074.
122. Kaufman CK, Mosimann C, Fan ZP, Yang S, Thomas AJ, Ablain J, Tan JL, Fogley RD, van Rooijen E, Hagedorn EJ, et al. 2016. A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation. Science 351: aad2197.
123. Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, Hammers H, Carducci MA. 2011. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. Eur J Cancer 47: 1955–1961.
124. Kesler CT, Liao S, Munn LL, Padera TP. 2013. Lymphatic vessels in health and disease. Wiley Interdiscip Rev Syst Biol Med 5: 111–124.
125. Koukourakis M, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter K, Harris A. 2003. Lactate dehydrogenase- 5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 89: 877–885.
126. Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, Dische S, Sivridis E, Harris AL. 2006. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 a and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHARTrandomized trial. J Clin Oncol 24: 727–735.
127. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT. 2010. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-a. Science 330: 827–830.
128. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. 2013. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31: 1219–1230.
129. Lee KE, Simon MC. 2012. From stem cells to cancer stem cells: HIF takes the stage. Curr Opin Cell Biol 24: 232–235.
130. Lee JJ, Perera RM, Wang H, Wu DC, Liu XS, Han S, Fitamant J, Jones PD, Ghanta KS, Kawano S, et al. 2014. Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc Natl Acad Sci 111: E3091–E3100.
131. Lehmann S, Stiehl DP, Honer M, Dominietto M, Keist R, Kotevic I, Wollenick K, Ametamey S, Wenger RH, Rudin M. 2009. Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events. Proc Natl Acad Sci 106: 14004–14009.
132. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, et al. 2009. Hypoxiainducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15: 501–513.
133. Lin EY, Nguyen AV, Russell RG, Pollard JW. 2001. Colonystimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193: 727–740.
134. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andren-Sandberg A, Domellof L. 1993. Pancreatitis and the risk of pancreatic cancer. N Engl J Med 328: 1433–1437.
135. Lu P, Weaver VM, Werb Z. 2012. The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol 196: 395–406.
136. MacLaurin J, Chapman J, Jones GW, Roose T. 2012. The buckling of capillaries in solid tumours. Proc Math Phys Eng Sci 468: rspa20120418.
137. Maes H, Kuchnio A, Peric A, Moens S, Nys K, De Bock K, Quaegebeur A, Schoors S, Georgiadou M, Wouters J, et al. 2014. Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell 26: 190–206.
138. Magee JA, Piskounova E, Morrison SJ. 2012. Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer Cell 21: 283–296.
139. Mantovani A. 2010. Molecular pathways linking inflammation and cancer. Curr Mol Med 10: 369–373.
140. Martin GR, Jain RK. 1994. Noninvasive measurement of interstitial pH profiles in normal and neoplastic tissue using fluorescence ratio imaging microscopy. Cancer Res 54: 5670–5674.
141. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ. 1996. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 14: 176–186.
142. Marusyk A, Almendro V, Polyak K. 2012. Intra-tumour heterogeneity: A looking glass for cancer?Nat Rev Cancer 12: 323–334.
143. Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F, Polyak K. 2014. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 514: 54–58.
144. Matus DQ, Lohmer LL, Kelley LC, Schindler AJ, Kohrman AQ, Barkoulas M, Zhang W, Chi Q, Sherwood DR. 2015. Invasive cell fate requires G1 cell-cycle arrest and histone deacetylase-mediated changes in gene expression. Dev Cell 35: 162–174.
145. Mayer A, Wree A, Höckel M, Leo C, Pilch H, Vaupel P. 2004. Lack of correlation between expression of HIF-1a protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. Cancer Res 64: 5876–5881.
146. Mazzone M, Dettori D, de Oliveira RL, Loges S, Schmidt T, Jonckx B, Tian YM, Lanahan AA, Pollard P, de Almodovar CR, et al. 2009. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136: 839–851.
147. McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OP, Sabbisetti VS, Bhatt RS, Simantov R, Choueiri TK. 2015. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res 21: 2471–2479.
148. Menter AR, Carroll N, Delate T, Hornbrook MC, Kushi LH, Sakoda L, Lee VS, Quinn VP, Adams JL, Ritzwoller DP. 2014. Effect of angiotensin system inhibitors on survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. 2014 ASCO Annual Meeting. Chicago, IL, May 30–June 3.
149. Mohyeldin A, Garzon-Muvdi T, Quinones-Hinojosa A. 2010. Oxygen in stem cell biology: A critical component of the stem cell niche. Cell Stem Cell 7: 150–161.
150. Morita T. 1995. Low pH leads to sister-chromatid exchanges and chromosomal aberrations, and its clastogenicity is Sdependent. Mutat Res 334: 301–308.
151. Motz GT, Coukos G. 2013. Deciphering and reversing tumor immune suppression. Immunity 39: 61–73.
152. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA. 2008. Identification of discrete tumorinduced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233–4244.
153. Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, Stobbe C, Hanks GE, Pollack A. 2002. Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: Preliminary findings. Urology 60: 634–639.
154. Mpekris F, Angeli S, Pirentis AP, Stylianopoulos T. 2015. Stress-mediated progression of solid tumors: Effect of mechanical stress on tissue oxygenation, cancer cell proliferation, and drug delivery. Biomech ModelMechanobiol 14: 1391–1402.
155. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF. 2008. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 11: 109–119.
156. Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. 2010. Heterogeneity of the tumor vasculature. In Seminars in thrombosis and hemostasis, Vol. 36, pp. 321–331. Thieme Medical, New York.
157. Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, Kogure H, Kawakubo K, Yagioka H, Yashima Y, et al. 2010. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 103: 1644–1648.
158. Nakai Y, Isayama H, Sasaki T, Takahara N, Saito K, Ishigaki K, Hamada T, Mizuno S, Miyabayashi K, Yamamoto K, et al. 2015. The inhibition of renin-angiotensin system in advanced pancreatic cancer: An exploratory analysis in 349 patients. J Cancer Res Clin Oncol 141: 933–939.
159. Naxerova K, Jain RK. 2015. Using tumour phylogenetics to identify the roots of metastasis in humans. Nat Rev Clin Oncol 12: 258–272.
160. Naxerova K, Brachtel E, Salk JJ, Seese AM, Power K, Abbasi B, Snuderl M, Chiang S, Kasif S, Jain RK. 2014. Hypermutable DNA chronicles the evolution of human colon cancer. Proc Natl Acad Sci 111: E1889–E1898.
161. Neri D, Supuran CT. 2011. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 10: 767–777.
162. Netti PA, Roberge S, Boucher Y, Baxter LT, Jain RK. 1996. Effect of transvascular fluid exchange on pressure-flow relationship in tumors: A proposed mechanism for tumor blood flow heterogeneity. Microvasc Res 52: 27–46.
163. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. 2000. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 60: 2497–2503.
164. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S. 2014. PD-L1 is a novel direct target of HIF-1a, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211: 781–790.
165. Noman MZ, Hasmim M, Messai Y, Terry S, Kieda C, Janji B, Chouaib S. 2015. Hypoxia: A key player in antitumor immune response. A review in the theme: Cellular responses to hypoxia. Am J Physiol Cell Physiol 309: C569–C579.
166. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, et al. 2005. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77: 18–24.
167. Noy R, Pollard JW. 2014. Tumor-associated macrophages: From mechanisms to therapy. Immunity 41: 49–61.
168. Ohlund D, Elyada E, Tuveson D. 2014. Fibroblast heterogeneity in the cancer wound. J Exp Med 211: 1503–1523.
169. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. 2005. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335–348.
170. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR, Danish H, Neck Cancer Study G. 2005. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6: 757–764.
171. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, et al. 2014. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25: 719–734.
172. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, et al. 2002. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296: 1883–1886.
173. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. 2004. Pathology: Cancer cells compress intratumour vessels. Nature 427: 695.
174. Padera TP, Meijer EF, Munn LL. 2016. The lymphatic system in disease processes and cancer progression. Annu Rev Biomed Eng 18: 125–158.
175. Palumbo A, Da Costa Nde O, Bonamino MH, Pinto LFR, Nasciutti LE. 2015. Genetic instability in the tumor microenvironment: A new look at an old neighbor. Mol Cancer 14: 1.
176. Papageorgis P, Stylianopoulos T. 2015. Role of TGFb in regulation of the tumor microenvironment and drug delivery (review). Int J Oncol 46: 933–943.
177. Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, Hudak JE, Lakins JN, Wijekoon AC, Cassereau L, et al. 2014. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature 511: 319–325.
178. Patenaude A, Woerher S, Umlandt P, Wong F, Ibrahim R, Kyle A, Unger S, Fuller M, Parker J, Minchinton A. 2015. A novel population of local pericyte precursor cells in tumor stroma that require Notch signaling for differentiation. Microvasc Res 101: 38–47.
179. Philip B, Ito K, Moreno-Sanchez R, Ralph SJ. 2013. HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression. Carcinogenesis 34: 1699–1707.
180. Pickup M, Novitskiy S, Moses HL. 2013. The roles of TGFb in the tumour microenvironment. Nat Rev Cancer 13: 788–799.
181. Pirentis AP, Polydorou C, Papageorgis P, Voutouri C, Mpekris F, Stylianopoulos T. 2015. Remodeling of extracellular matrix due to solid stress accumulation during tumor growth. Connect Tissue Res 56: 345–354.
182. Plaks V, Kong N, Werb Z. 2015. The cancer stem cell niche: How essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 16: 225–238.
183. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. 2012. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21: 418–429.
184. Pugh CW, Ratcliffe PJ. 2003. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 9: 677–684.
185. Raza A, Franklin MJ, Dudek AZ. 2010. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol 85: 593–598.
186. Regan DP, Guth AM, Hansen RJ, Gustafson DL, Dow SW. 2016. Angiotensin II type 1 receptor antagonism suppresses tumor metastasis through inhibition of CCL2- CCR2 mediated monocyte recruitment. Cancer Immunol Res 4: A161–A161.
187. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, et al. 2014. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25: 735–747.
188. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, et al. 2010. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468: 824–828.
189. Riemann A, Wussling H, Loppnow H, Fu H, Reime S, Thews O. 2016. Acidosis differently modulates the inflammatory program in monocytes and macrophages. Biochim Biophys Acta 1862: 72–81.
190. Rivera LB, Bergers G. 2015. Cancer. Tumor angiogenesis, from foe to friend. Science 349: 694–695.
191. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR. 2003. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 63: 8360–8365.
192. Ronnov-Jessen L, Petersen OW, Bissell MJ. 1996. Cellular changes involved in conversion of normal to malignant breast: Importance of the stromal reaction. Physiol Rev 76: 69–125.
193. Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R, Lipponen P, Ågren U, Alhava E, Kosma VM. 1998. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 58: 342–347.
194. Sadeghi N, Abbruzzese JL, Yeung SCJ, Hassan M, Li D. 2012. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 18: 2905–2912.
195. Samani A, Zubovits J, Plewes D. 2007. Elastic moduli of normal and pathological human breast tissues: An inversion- technique-based investigation of 169 samples. Phys Med Biol 52: 1565–1576.
196. Sauvant C, Nowak M, Wirth C, Schneider B, Riemann A, Gekle M, Thews O. 2008. Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38. Int J Cancer 123: 2532–2542.
197. Scherz-Shouval R, Santagata S, Mendillo ML, Sholl LM, Ben-Aharon I, Beck AH, Dias-Santagata D, Koeva M, Stemmer SM, Whitesell L, et al. 2014. The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. Cell 158: 564–578.
198. Semenza GL. 2012. Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol Med 18: 534–543.
199. Semenza GL. 2014. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol 9: 47–71.
200. Semenza GL. 2016. Dynamic regulation of stem cell specification and maintenance by hypoxia-inducible factors. Mol Aspects Med 47–48: 15–23.
201. Sevick EM, Jain RK. 1989. Viscous resistance to blood flow in solid tumors: Effect of hematocrit on intratumor blood viscosity. Cancer Res 49: 3513–3519.
202. Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, et al. 2014. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159: 80–93.
203. Shweiki D, Itin A, Soffer D, Keshet E. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843–845.
204. Singhal PK, Sassi S, Lan L, Au P, Halvorsen SC, Fukumura D, Jain RK, Seed B. 2016. Mouse embryonic fibroblasts exhibit extensive developmental and phenotypic diversity. Proc Natl Acad Sci 113: 122–127.
205. Sledge GW. 2015. Anti-vascular endothelial growth factor therapy in breast cancer: Game over? J Clin Oncol 33: 133–135.
206. Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, Pastorino S, Yang M, Hoffman RM, Kesari S. 2011. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci 108: 4274–4280.
207. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, et al. 2009. A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69: 5296–5300.
208. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT, et al. 2012. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72: 402–407.
209. Spivak-Kroizman TR, Hostetter G, Posner R, Aziz M, Hu C, Demeure MJ, Von Hoff D, Hingorani SR, Palculict TB, Izzo J, et al. 2013. Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Res 73: 3235–3247.
210. Stylianopoulos T, Jain RK. 2013. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci 110: 18632–18637.
211. Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N, Smith BL, Ferrone CR, Hornicek FJ, Boucher Y, et al. 2012. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci 109: 15101–15108.
212. Stylianopoulos T, Martin JD, Snuderl M, Mpekris F, Jain SR, Jain RK. 2013. Coevolution of solid stress and interstitial fluid pressure in tumors during progression: Implications for vascular collapse. Cancer Res 73: 3833–3841.
213. Sugimoto H, Mundel TM, Kieran MW, Kalluri R. 2006. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5: 1640–1646.
214. Tabassum DP, Polyak K. 2015. Tumorigenesis: It takes a village. Nat Rev Cancer 15: 473–483.
215. Taghian AG, Abi-Raad R, Assaad SI, Casty A, Ancukiewicz M, Yeh E, Molokhia P, Attia K, Sullivan T, Kuter I, et al. 2005. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: Clinical implications. J Clin Oncol 23: 1951–1961.
216. Tan E, Yan M, Campo L, Han C, Takano E, Turley H, Candiloro I, Pezzella F, Gatter K, Millar E. 2009. The key hypoxia regulated gene CAIX is upregulated in basallike breast tumours and is associated with resistance to chemotherapy. Br J Cancer 100: 405–411.
217. Thiery JP, Acloque H, Huang RY, Nieto MA. 2009. Epithelial- mesenchymal transitions in development and disease. Cell 139: 871–890.
218. Thomlinson R, Gray L. 1955. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9: 539.
219. Tlsty TD, Coussens LM. 2006. Tumor stroma and regulation of cancer development. Annu Rev Pathol 1: 119–150.
220. Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, Barry WT, Goel S, Lahdenrata J, Isakoff SJ, et al. 2015. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci 112: 14325–14330.
221. Tse JM, Cheng G, Tyrrell JA, Wilcox-Adelman SA, Boucher Y, Jain RK, Munn LL. 2012. Mechanical compression drives cancer cells toward invasive phenotype. Proc Natl Acad Sci 109: 911–916.
222. Tung JC, Barnes JM, Desai SR, Sistrunk C, Conklin MW, Schedin P, Eliceiri KW, Keely PJ, Seewaldt VL, Weaver VM. 2015. Tumor mechanics and metabolic dysfunction. Free Radic Biol Med 79: 269–280.
223. Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324: 1029–1033.
224. Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, et al. 2012. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: Implications for scheduling of anti-angiogenic drugs. Cancer Cell 21: 82–91.
225. van Malenstein H, Gevaert O, Libbrecht L, Daemen A, Allemeersch J, Nevens F, Van Cutsem E, Cassiman D, De Moor B, Verslype C, et al. 2010. A seven-gene set associated with chronic hypoxia of prognostic importance in hepatocellular carcinoma. Clin Cancer Res 16: 4278–4288.
226. Vasudev NS, Reynolds AR. 2014. Anti-angiogenic therapy for cancer: Current progress, unresolved questions and future directions. Angiogenesis 17: 471–494.
227. Vaupel P, Mayer A. 2014. Hypoxia in tumors: Pathogenesisrelated classification, characterization of hypoxia subtypes, and associated biological and clinical implications. In Oxygen transport to tissue XXXVI, pp. 19–24. Springer, New York.
228. 2 histography. Antioxid Redox Signal 9: 1221–1236.
229. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. 2013. Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine. N Engl J Med 369: 1691–1703.
230. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C, Tabar V. 2010. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468: 829–833.
231. Ward PS, Thompson CB. 2012. Metabolic reprogramming: A cancer hallmark evenWarburg did not anticipate. Cancer Cell 21: 297–308.
232. Whatcott CJ, Diep CH, Jiang P, Watanabe A, LoBello J, Sima C, Hostetter G, Shepard HM, Von Hoff DD, Han H. 2015a. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res 21: 3561–3568.
233. Whatcott CJ, Han H, Von Hoff DD. 2015b. Orchestrating the tumor microenvironment to improve survival for patients with pancreatic cancer: Normalization, not destruction. Cancer J 21: 299–306.
234. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. 2009. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 135: 1429–1435.
235. Wilson WR, Hay MP. 2011. Targeting hypoxia in cancer therapy. Nat Rev Cancer 11: 393–410.
236. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, et al. 2004. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6: 553–563.
237. Wojtkowiak JW, Rothberg JM, Kumar V, Schramm KJ, Haller E, Proemsey JB, Lloyd MC, Sloane BF, Gillies RJ. 2012. Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments. Cancer Res 72: 3938–3947.
238. Wong P-P, Demircioglu F, Ghazaly E, Alrawashdeh W, Stratford MR, Scudamore CL, Cereser B, Crnogorac-Jurcevic T, McDonald S, Elia G. 2015. Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer Cell 27: 123–137.
239. Wrzesinski SH, Wan YY, Flavell RA. 2007. Transforming growth factor-b and the immune response: Implications for anticancer therapy. Clin Cancer Res 13: 5262–5270.
240. Yan M, Rayoo M, Takano E, Thorne H, Fox S. 2009. BRCA1 tumours correlate with a HIF-1a phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. Br J Cancer 101: 1168–1174.
241. Yang SX, Steinberg SM, Nguyen D, Wu TD, Modrusan Z, Swain SM. 2008. Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res 14: 5893–5899.
242. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. 1994. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 54: 4564–4568.
243. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS, Kalluri R. 2015. Epithelial-tomesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527: 525–530.
244. Zlotek-Zlotkiewicz E, Monnier S, Cappello G, Le Berre M, Piel M. 2015. Optical volume and mass measurements show that mammalian cells swell during mitosis. J Cell Biol 211: 765–774.
245. Zustiak S, Nossal R, Sackett DL. 2014. Multiwell stiffness assay for the study of cell responsiveness to cytotoxic drugs. Biotechnol Bioeng 111: 396–403.